ArticleOncotarget2018
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.International journal of clinical oncology · 2024Pooled it
- Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial.Signal transduction and targeted therapy · 2024Trial
- Trial
- A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).International journal of clinical oncology · 2021Trial
- High therapeutic efficacy of triplet therapy in unresectable or metastatic colorectal cancer and its optimal application strategies.International journal of clinical oncology · 2026Review
- ConcomitantJournal of the anus, rectum and colon · 2026Article
- Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam.OncoTargets and therapy · 2026Article
- Primary Choriocarcinoma of Colon: Case Report and Literature Review.Journal of the anus, rectum and colon · 2025Article
- Review
- Trial Protocol of a Phase II Study of mFOLFOXIRI after Metastasectomy in Patients with Oligometastatic Colorectal Cancer (FANTASTIC Study).Journal of the anus, rectum and colon · 2024Article
- Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.International journal of colorectal disease · 2022Article
- Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.Targeted oncology · 2021Review
- Perspectives in the Treatment ofFrontiers in oncology · 2021Article
- Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis.Translational cancer research · 2020Article
- Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.Internal medicine (Tokyo, Japan) · 2020Article
- Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma.Cancer management and research · 2020Article
- The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.Drugs · 2019Review
- Rab23 contributes to the progression of colorectal cancer via protein kinase B and extracellular signal-regulated kinase signaling pathways.Oncology letters · 2019Article
- Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study.Oncotarget · 2019Article
- Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients.Frontiers in oncology · 2019Article
Corrections and comments
- Erratum issuedCorrection: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.2018 · Ichikawa, Wararu [corrected to Ichikawa, Wataru]
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FOLFOXIRI plus bevacizumab is considered a standard initial therapy for metastatic colorectal cancer (mCRC). However, few prospective trials have evaluated triplet therapy plus bevacizumab in patients with RAS mutant mCRC. Patients with an age of 20 to 75 years, and unresectable, measurable tumors harboring RAS mutation were given first-line treatment with bevacizumab (5 mg/kg on day 1) plus modified-FOLFOXIRI (irinotecan 150 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.